ALTAltimmune, Inc.
$2.60-34% 1Y
$2.60
$2.5952 weeks$6.18
Price
-34%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, the market against it.
P/En/a
Market value$505.6M
1 year-34%
5 years-77%
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $41K (+105% year on year) and net income −$88M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.Director or officer change · Form 8-K
- Aug 12, 2026Altimmune Announces Second Quarter 2026 Financial Results and Business Update.Earnings release · press release
- Jul 28, 2026As noted above, on July 28, 2026, the Company announced the positive topline results from the RECLAIM Phase 2 trial evaluating the 2.4 mg dose of pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe AUD. The trial met its primary endpoint with a highly …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.